GlaxoSmithKline [NYSE: GSK] confirmed that it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical trial at the request of the U.S. Food and Drug Administration (FDA) pending FDA review of recommendations from its Advisory Committee meeting July 13-14.

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2010.

Novartis delivered a strong performance in the second quarter of 2010 - with the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines - as the Group made progress on its agenda on innovation, growth and productivity.

Bayer Schering Pharma AG, Germany, has entered into a research collaboration agreement with The People's Liberation Army General Hospital (301 Hospital) in Beijing, China.

Amgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.

Mylan Inc. (Nasdaq: MYL) has announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash.

The Amgen Foundation is supporting an online competition with Ashoka's Changemakers to find the best solutions that elevate patients' voices to improve health outcomes globally.